Thirty Years of Pneumococcal Conjugate Vaccines in Children: Achievements, Challenges and Lessons From a Moving Target.

Abstract

Aim: To review the long-term epidemiological and immunological impact of pneumococcal conjugate vaccines (PCVs) in the context of serotype replacement and the development of higher-valency formulations.

Methods: Brief literature overview of current evidence on pneumococcal biology, natural and vaccine-induced immunity, population-level effects of PCVs and the epidemiological dynamics of serotype distribution.

Results: PCVs have profoundly reshaped the landscape of paediatric infectious diseases, leading to a dramatic decline in Streptococcus pneumoniae infections in children and, through herd protection, in adults. The decline in vaccine-type infections has been partially offset by the gradual emergence of non-vaccine serotypes. However, despite this serotype replacement, PCVs remain among the most powerful paediatric vaccines ever developed. The diversity of pneumococcal biology, the interplay between natural and vaccine-induced immunity and the dynamic process of serotype replacement create a constantly moving target. The introduction of higher-valency vaccines, now including up to 15 or 20 serotypes, seeks to address this adaptation but faces intrinsic immunological limits.

Conclusion: Three decades after the first clinical trials, our understanding of their long-term epidemiological and immunological impact is still evolving. Future vaccine strategies must optimize the balance between expanded serotype coverage and durable immune protection at both the individual and population levels.